Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Contributed by: PR Newswire

Tags

ONCOINVENT-Clinical

More Like This

Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy

Prof. Dean Fennell, Director of the Mesothelioma Research Programme at Leicester University Hospitals in the lab with Dr. Joanna Dzialo and Dr. Aleksandra Bzura. The research and clinical teams are investigating RSO-021 anticancer activity in patients with malignant pleural mesothelioma and metastatic disease to the lung. (Photo: Dan Ryan)

RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Professor Dean Fennell, principal investigator, presents results from the Phase 1 MITOPE clinical study of a first-in-human, and potential first-in-class therapeutic, RSO-021. (Photo: Business Wire)

RS Oncology Announces Positive Data from a Phase 1 Clinical Trial of RSO-021, a First-in-Class Therapeutic for Malignant Pleural Mesothelioma